Anyone pay attention to this discussion?
--(BW HealthWire)--June 11, 1998--
Robert Strauss Discusses Novartis Joint Venture, Women's Hormone Replacement Therapy Drug, Marketing Plan and New Product Line-Up
WHO: Robert Strauss, President and CEO, Noven Pharmaceuticals
Inc. (NASDAQ:NOVN)
WHERE: The entire interview can be heard via the Internet at
Stock-Line's Web site, "www.stock-line.com."
WHAT: Interview on Stock-Line, the stock traders' news network.
The Interview comes on the heels of Solomon Smith Barney
"Buy" Rating that occurred one day earlier.
Noven Pharmaceuticals and Novartis recently formed a joint
venture that initially focuses on the marketing of Vivelle,
a hormone replacement transdermal patch that has unique
advantages over its competitors.
The joint venture gives Noven substantial control and
influence over Vivelle sales in the U.S. market, the
largest pharmaceutical market in the world.
Strauss added in the interview that in the future, other
products aimed at the women's health market might be
added to the JV "that will help form a women's product
line."
Noven Pharmaceuticals researches, develops, manufactures
and markets leading innovative prescription drugs used to
treat a number of diseases and conditions.
WHEN: The interview was conducted on June 10, 1998. It will run
on Stock-Line through June 14, 1998.
WHERE: If you would like to arrange an interview with Robert
Strauss or require additional information, contact
Jonathan Mayer or Alec Rosen at 305/672-4422.
CONTACT: Noven Pharmaceuticals
Jonathan Mayer or Alec Rosen
305/672-4422
e-mail: jonathan@zynyx.com or alec@zynyx.com |
